Solid Biosciences

Solid Biosciences

Biotechnology
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

$734.5M

Market Cap • 10/2/2026

2013

(13 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

2

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

3,5

EPS

—

Market Cap

Market Cap

734,5M

EV

376,3M

EV/Revenue

0

EV/EBITDA

-1,8

EV/EBIT

-1,8

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-41,9%

Total Yield

-41,9%

Payout

0%

Retained Earnings

-1,1B

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

59,2%

Capex/OCF

-0,5%

SBC/OCF

—

% PPE

5,9%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

22,1%

CAGR Net Income 5Y

21,5%

CAGR EPS 5Y

-35,1%

CAGR OCF 5Y

28,8%

Leverage

N.D./EBITDA

1,7

Debt/Equity

0%

Current Ratio

13,8

Quick Ratio

13,2

Interest Coverage

64094,6%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium